Abstract
Targeting the mammalian target of rapamycin (mTOR) protein is a promising strategy for cancer therapy. The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs. We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation. We demonstrate that PP242, but not rapamycin, causes death of mouse and human leukemia cells. In vivo, PP242 delays leukemia onset and augments the effects of the current front-line tyrosine kinase inhibitors more effectively than does rapamycin. Unexpectedly, PP242 has much weaker effects than rapamycin on the proliferation and function of normal lymphocytes. PI-103, a less selective TORC1/2 inhibitor that also targets phosphoinositide 3-kinase (PI3K), is more immunosuppressive than PP242. These findings establish that Ph+ transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Engelman, J.A., Luo, J. & Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606–619 (2006).
Manning, B.D. & Cantley, L.C. AKT/PKB signaling: navigating downstream. Cell 129, 1261–1274 (2007).
Samuels, Y. & Ericson, K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18, 77–82 (2006).
Martelli, A.M. et al. Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol. Histopathol. 20, 239–252 (2005).
Wee, S. et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286–4293 (2009).
Yap, T.A. et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls and promises. Curr. Opin. Pharmacol. 8, 393–412 (2008).
Abraham, R.T. Regulation of the mTOR signaling pathway: from laboratory bench to bedside and back again. F1000 Biology Reports 1, 8 (2009).
Guertin, D.A. & Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell 12, 9–22 (2007).
Abraham, R.T. & Eng, C.H. Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin. Ther. Targets 12, 209–222 (2008).
Guertin, D.A. & Sabatini, D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2, pe24 (2009).
Janes, M.R. & Fruman, D.A. Immune regulation by rapamycin: moving beyond T cells. Sci. Signal. 2, pe25 (2009).
Thomson, A.W., Turnquist, H.R. & Raimondi, G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9, 324–337 (2009).
Choo, A.Y., Yoon, S.O., Kim, S.G., Roux, P.P. & Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA 105, 17414–17419 (2008).
Feldman, M.E. et al. Active-Site Inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
García-Martínez, J.M. et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29–42 (2009).
Thoreen, C.C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023–8032 (2009).
Yu, K. et al. Biochemical, cellular and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69, 6232–6240 (2009).
Chiarini, F. et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 69, 3520–3528 (2009).
Kharas, M.G. et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest. 118, 3038–3050 (2008).
Kojima, K., et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22, 1728–1736 (2008).
Park, S. et al. PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22, 1698–1706 (2008).
Burgess, M.R. & Sawyers, C.L. Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal 6, 918–930 (2006).
Druker, B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808–4817 (2008).
Li, S., Ilaria, R.L. Jr., Million, R.P., Daley, G.Q. & Van Etten, R.A. The P190, P210 and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189, 1399–1412 (1999).
Raynaud, F.I. et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67, 5840–5850 (2007).
Maira, S.M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851–1863 (2008).
Gruber, F., Mustjoki, S. & Porkka, K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome–positive acute lymphoblastic leukaemia. Br. J. Haematol. 145, 581–597 (2009).
Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias. N. Engl. J. Med. 354, 2531–2541 (2006).
Hu, Y. et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. USA 103, 16870–16875 (2006).
McCubrey, J.A. et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22, 708–722 (2008).
Foa, R. et al. Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study. Blood 112, abstract 305 (2008).
Prabhu, S. et al. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 26, 1188–1200 (2007).
Zhang, M. et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol. Cell. Biol. 28, 6496–6509 (2008).
Hedrick, S.M. The cunning little vixen: Foxo and the cycle of life and death. Nat. Immunol. 10, 1057–1063 (2009).
Huang, H. & Tindall, D.J. Dynamic FoxO transcription factors. J. Cell Sci. 120, 2479–2487 (2007).
Copp, J., Manning, G. & Hunter, T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69, 1821–1827 (2009).
García-Martínez, J.M. & Alessi, D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416, 375–385 (2008).
Kennedy, J.A. & Barabe, F. Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. Leukemia 22, 2029–2040 (2008).
Sarbassov, D.D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006).
Mohi, M.G. et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. USA 101, 3130–3135 (2004).
Luo, F.R. et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin. Cancer Res. 12, 7180–7186 (2006).
Sankhala, K. et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target. Oncol. 4, 135–142 (2009).
Durand, C.A. et al. Phosphoinositide 3-kinase p110δ regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 183, 5673–5684 (2009).
Delgoffe, G.M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832–844 (2009).
Sharma, S.V., Fischbach, M.A., Haber, D.A. & Settleman, J. 'Oncogenic shock': explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 12, 4392s–4395s (2006).
Shor, B., Cavender, D. & Harris, C. A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice. BMC Immunol. 10, 28 (2009).
Fruman, D.A. & Bismuth, G. Fine tuning the immune response with PI3K. Immunol. Rev. 228, 253–272 (2009).
Lopez-Fauqued, M., et al. The dual PI3K/mTOR inhibitor (PI-103) promotes immunosupression, in vivo tumor growth and increases survival of sorafenib treated melanoma cells. Int. J. Cancer published online, doi:10.1002/ijc.24926 (6 October 2009).
Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691–699 (2008).
Acknowledgements
We thank K. Shokat, T. Wilson, and M. Kharas for support and helpful discussions and R. Nguyen for constructing BCR-ABL mutants. For access to the LSM710 Zeiss confocal microscope we thank E. Gratton's laboratory in the Department of Biomedical Engineering, University of California–Irvine. The SUP-B15 cells stably expressing firefly luciferase (SUP-B15ffLuc) were a kind gift from M. Jensen (City of Hope). Technical assistance was provided through the Optical Biology Core facility of the Developmental Biology Center, a shared resource supported in part by the Cancer Center Support Grant (CA-62203) and the Center for Complex Biological Systems Support Grant (GM-076516) at the University of California–Irvine. The Lumina IVIS bioluminescent imager was supported by a grant to the University of California–Irvine from the California Institute of Regenerative Medicine. This work was supported by US National Institutes of Health training grant T32-CA009054 (to M.R.J.), National Institutes of Health Minority Access to Research Careers grant T34GM069337 (to M.A.C.), a Research Scholar Grant from the American Cancer Society (to D.A.F.), a Discovery Grant from the University of California Industry–University Cooperative Research Program (to D.A.F.), a sponsored research agreement from Intellikine, Inc. (to D.A.F.) and a Bridge award from the Chao Family Comprehensive Cancer Center. M.R.J. is an awardee of the Jackie Murphy and Carol Malouf Scholar Achievement Rewards for College Scientists.
Author information
Authors and Affiliations
Contributions
M.R.J. designed and performed experiments, analyzed data and wrote the manuscript. J.J.L., L.S., J.C. and C.V. designed and performed experiments and analyzed data. M.A.C., R.J.L. and S.M. performed experiments and analyzed data. M.B.L., S.T.O. and M.K. provided clinical samples, analyzed data and edited the manuscript. M.B.M. and P.R. provided materials and supervised groups performing chemical synthesis and formulation. Y.L. and C.R. designed and supervised experiments and edited the manuscript. D.A.F. designed and supervised experiments and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
M.B.M., P.R., Y.L. and C.R. are employees of Intellikine, a company developing mTOR inhibitors for therapeutic use. D.A.F. is a member of the Scientific Advisory Board of Intellikine.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–8, Supplementary Tables 1–4 and Supplementary Methods (PDF 9371 kb)
Rights and permissions
About this article
Cite this article
Janes, M., Limon, J., So, L. et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16, 205–213 (2010). https://doi.org/10.1038/nm.2091
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2091
This article is cited by
-
Detoxified pneumolysin derivative ΔA146Ply inhibits autophagy and induces apoptosis in acute myeloid leukemia cells by activating mTOR signaling
Experimental & Molecular Medicine (2022)
-
Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR
Cell Death & Disease (2022)
-
Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer
Medical Oncology (2022)
-
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
Investigational New Drugs (2022)
-
Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways
Cancer Cell International (2021)